Waterdrop announces integration of DeepSeek
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2025
0mins
Should l Buy WDH?
Strategic Integration: Waterdrop has announced its strategic integration with DeepSeek to enhance business growth.
AI Innovation in Insurance: The collaboration aims to drive innovative applications of large-scale AI models within specialized insurance scenarios.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WDH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WDH
About WDH
Waterdrop Inc is a holding company principally engaged in the provision of insurance and healthcare service. The Company mainly operates through three segments. The Insurance segment is primarily engaged in the provision of insurance brokerage service, such as health and life insurance products, as well as technical service. The Crowdfunding segment is primarily engaged in the provision of crowdfunding service. The Others segment include online sale of health products, and the provision of digital multichannel marketing solution and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Waterdrop Files Annual Report for 2025
- Annual Report Filing: Waterdrop Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the SEC on April 28, 2026, demonstrating the company's ongoing commitment to transparency and compliance.
- Financial Information Access: Investors can access the annual report via the company's investor relations website and the SEC's site, ensuring timely access to audited financial statements and enhancing communication with shareholders.
- Shareholder Service Commitment: The company offers to provide a hard copy of the annual report containing audited consolidated financial statements free of charge upon shareholder request, reflecting its dedication to shareholder rights and service.
- Company Background Overview: Founded in 2016, Waterdrop is dedicated to providing insurance and healthcare services to billions through technology, showcasing its positive social impact and commitment to improving access to essential services.
See More
Waterdrop Inc. Files Annual Report for FY 2025
- Annual Report Filing: Waterdrop Inc. filed its Form 20-F annual report for the fiscal year ending December 31, 2025, with the SEC on April 28, 2026, reflecting the company's ongoing commitment to transparency and compliance.
- Financial Information Access: Investors can access the annual report via the company's website and the SEC's site, ensuring timely availability of audited financial statements and enhancing trust between the company and its investors.
- Shareholder Services: The company offers to provide a hard copy of the annual report containing audited consolidated financial statements free of charge upon shareholder request, demonstrating its commitment to shareholder rights and service.
- Company Background: Founded in 2016, Waterdrop Inc. aims to leverage technology to provide insurance and healthcare services to billions, showcasing its leadership in the insurance market and positive social impact.
See More
Waterdrop (WDH) Q4 2025 Earnings Call Transcript
See More
Waterdrop Inc. Announces 2025 Financial Results and Dividend
- Significant Revenue Growth: Waterdrop reported net operating revenue of RMB 1.411 billion in Q4 2025, reflecting a 105.5% year-over-year increase, indicating strong momentum in insurance-related income and sustained profitability for the sixteenth consecutive quarter.
- Strong Insurance Performance: In 2025, insurance-related income reached RMB 3.577 billion, a 51.3% year-over-year increase, with Q4 revenue of RMB 1.312 billion up 125.0%, highlighting significant improvements in technical service income that further solidify market positioning.
- Remarkable Medical Crowdfunding Impact: As of December 31, 2025, Waterdrop Medical Crowdfunding raised RMB 72.3 billion for 3.68 million patients, showcasing the company's strong influence in emergency rescue, while upgraded risk control systems effectively mitigated data theft risks.
- Continued Growth in Digital Clinical Trials: Waterdrop's Digital Clinical Trial Solution generated RMB 118.3 million in 2025, a 29.9% year-over-year increase, successfully enrolling 14,555 patients into 1,611 clinical trial programs, demonstrating the company's innovative capabilities in intelligent drug-patient matching technology.
See More
Waterdrop Declares $0.03 Quarterly Dividend per ADS
- Quarterly Dividend Announcement: Waterdrop has declared a quarterly dividend of $0.03 per ADS, consistent with previous distributions, indicating the company's stable cash flow and profitability, which helps bolster investor confidence.
- Payment and Record Dates: The dividend will be payable on May 13 for ordinary shareholders and around May 20 for ADS holders, with a record date of April 24, demonstrating the company's transparency and consistency in its dividend policy.
- Financial Performance Overview: Waterdrop reported a GAAP EPS of $0.01 and revenue of $201.81 million, showing low profitability but indicating revenue growth that highlights the company's market potential in China's InsurTech sector.
- Market Focus: Amid fears of AI disruption, Waterdrop is recognized as a top-rated insurance broker by Seeking Alpha's Quant Rating, reflecting market attention on its future growth and recognition of its business model.
See More
Waterdrop Inc. Reports Significant Revenue Growth in 2025 Financial Results
- Surge in Insurance Revenue: In Q4 2025, Waterdrop's insurance-related income soared by 125% year-over-year, driven by AI models that efficiently manage high concurrency, significantly enhancing competitive positioning.
- Substantial Revenue Growth: The company's net operating revenue for Q4 2025 reached RMB 1.411 billion (approximately USD 201.8 million), marking a 105.5% year-over-year increase, indicating strong performance in the insurance sector.
- Shareholder Return Initiatives: By the end of February 2026, Waterdrop had repurchased approximately 60.7 million ADSs for about USD 118.1 million and plans to distribute a cash dividend of approximately USD 10.8 million, reflecting a strong commitment to shareholder returns.
- Innovation in Digital Clinical Trials: The company secured a national invention patent for China's first intelligent drug-patient matching technology, facilitating collaborations with 224 pharmaceutical companies and contract research organizations, with patient enrollment reaching 1,273, driving a 39.9% year-over-year revenue increase.
See More
Waterdrop Files Annual Report for 2025
- Annual Report Filing: Waterdrop Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the SEC on April 28, 2026, demonstrating the company's ongoing commitment to transparency and compliance.
- Financial Information Access: Investors can access the annual report via the company's investor relations website and the SEC's site, ensuring timely access to audited financial statements and enhancing communication with shareholders.
- Shareholder Service Commitment: The company offers to provide a hard copy of the annual report containing audited consolidated financial statements free of charge upon shareholder request, reflecting its dedication to shareholder rights and service.
- Company Background Overview: Founded in 2016, Waterdrop is dedicated to providing insurance and healthcare services to billions through technology, showcasing its positive social impact and commitment to improving access to essential services.
See More
Waterdrop Inc. Files Annual Report for FY 2025
- Annual Report Filing: Waterdrop Inc. filed its Form 20-F annual report for the fiscal year ending December 31, 2025, with the SEC on April 28, 2026, reflecting the company's ongoing commitment to transparency and compliance.
- Financial Information Access: Investors can access the annual report via the company's website and the SEC's site, ensuring timely availability of audited financial statements and enhancing trust between the company and its investors.
- Shareholder Services: The company offers to provide a hard copy of the annual report containing audited consolidated financial statements free of charge upon shareholder request, demonstrating its commitment to shareholder rights and service.
- Company Background: Founded in 2016, Waterdrop Inc. aims to leverage technology to provide insurance and healthcare services to billions, showcasing its leadership in the insurance market and positive social impact.
See More
Waterdrop (WDH) Q4 2025 Earnings Call Transcript
See More
Waterdrop Inc. Announces 2025 Financial Results and Dividend
- Significant Revenue Growth: Waterdrop reported net operating revenue of RMB 1.411 billion in Q4 2025, reflecting a 105.5% year-over-year increase, indicating strong momentum in insurance-related income and sustained profitability for the sixteenth consecutive quarter.
- Strong Insurance Performance: In 2025, insurance-related income reached RMB 3.577 billion, a 51.3% year-over-year increase, with Q4 revenue of RMB 1.312 billion up 125.0%, highlighting significant improvements in technical service income that further solidify market positioning.
- Remarkable Medical Crowdfunding Impact: As of December 31, 2025, Waterdrop Medical Crowdfunding raised RMB 72.3 billion for 3.68 million patients, showcasing the company's strong influence in emergency rescue, while upgraded risk control systems effectively mitigated data theft risks.
- Continued Growth in Digital Clinical Trials: Waterdrop's Digital Clinical Trial Solution generated RMB 118.3 million in 2025, a 29.9% year-over-year increase, successfully enrolling 14,555 patients into 1,611 clinical trial programs, demonstrating the company's innovative capabilities in intelligent drug-patient matching technology.
See More
Waterdrop Declares $0.03 Quarterly Dividend per ADS
- Quarterly Dividend Announcement: Waterdrop has declared a quarterly dividend of $0.03 per ADS, consistent with previous distributions, indicating the company's stable cash flow and profitability, which helps bolster investor confidence.
- Payment and Record Dates: The dividend will be payable on May 13 for ordinary shareholders and around May 20 for ADS holders, with a record date of April 24, demonstrating the company's transparency and consistency in its dividend policy.
- Financial Performance Overview: Waterdrop reported a GAAP EPS of $0.01 and revenue of $201.81 million, showing low profitability but indicating revenue growth that highlights the company's market potential in China's InsurTech sector.
- Market Focus: Amid fears of AI disruption, Waterdrop is recognized as a top-rated insurance broker by Seeking Alpha's Quant Rating, reflecting market attention on its future growth and recognition of its business model.
See More
Waterdrop Inc. Reports Significant Revenue Growth in 2025 Financial Results
- Surge in Insurance Revenue: In Q4 2025, Waterdrop's insurance-related income soared by 125% year-over-year, driven by AI models that efficiently manage high concurrency, significantly enhancing competitive positioning.
- Substantial Revenue Growth: The company's net operating revenue for Q4 2025 reached RMB 1.411 billion (approximately USD 201.8 million), marking a 105.5% year-over-year increase, indicating strong performance in the insurance sector.
- Shareholder Return Initiatives: By the end of February 2026, Waterdrop had repurchased approximately 60.7 million ADSs for about USD 118.1 million and plans to distribute a cash dividend of approximately USD 10.8 million, reflecting a strong commitment to shareholder returns.
- Innovation in Digital Clinical Trials: The company secured a national invention patent for China's first intelligent drug-patient matching technology, facilitating collaborations with 224 pharmaceutical companies and contract research organizations, with patient enrollment reaching 1,273, driving a 39.9% year-over-year revenue increase.
See More
